Quantitative MRI for Analysis of Active Multiple Sclerosis Lesions without Gadolinium-Based Contrast Agent

References

1. 1.↵
   2. Rocca MA,
   3. Anzalone N,
   4. Falini A, et al

   . Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis. Radiol Med 2013;118:251–64 doi:10.1007/s11547-012-0811-3 pmid:22430683

   CrossRefPubMed
2. 2.↵
   2. Polman CH,
   3. Reingold SC,
   4. Banwell B, et al

   . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Coyle PK

   . Switching therapies in multiple sclerosis. CNS Drugs 2013;27:239–47 doi:10.1007/s40263-013-0042-5 pmid:23508518

   CrossRefPubMed
4. 4.↵
   2. Barkhof F

   . The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–45 doi:10.1097/00019052-200206000-00003 pmid:12045719

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Thomsen HS,
   3. Morcos SK,
   4. Almén T, et al

   ; ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013;23:307–18 doi:10.1007/s00330-012-2597-9 pmid:22865271

   CrossRefPubMed
6. 6.↵
   2. Prince MR,
   3. Zhang H,
   4. Zou Z, et al

   . Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011;196:W138–43 doi:10.2214/AJR.10.4885 pmid:21257854

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Kanda T,
   3. Ishii K,
   4. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
8. 8.↵
   2. Errante Y,
   3. Cirimele V,
   4. Mallio CA, et al

   . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

   CrossRefPubMed
9. 9.↵
   2. McDonald RJ,
   3. McDonald JS,
   4. Kallmes DF, et al

   . Intracranial gadolinium deposition after contrast-enhanced MRI. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

   CrossRefPubMed
10. 10.↵
    2. Wiggermann V,
    3. Hernández Torres E,
    4. Vavasour IM, et al

    . Magnetic resonance frequency shifts during acute MS lesion formation. Neurology 2013;81:211–18 doi:10.1212/WNL.0b013e31829bfd63 pmid:23761621

    Abstract/FREE Full Text
11. 11.↵
    2. Levesque IR,
    3. Giacomini PS,
    4. Narayanan S, et al

    . Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions. Magn Reson Med 2010;63:633–40 doi:10.1002/mrm.22244 pmid:20146232

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Jurcoane A,
    3. Wagner M,
    4. Schmidt C, et al

    . Within-lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis. J Magn Reson Imaging 2013;38:1454–61 doi:10.1002/jmri.24107 pmid:23554005

    CrossRefPubMed
13. 13.↵
    2. Warntjes JB,
    3. Dahlqvist O,
    4. Lundberg P

    . Novel method for rapid, simultaneous T1, T*2, and proton density quantification. Magn Reson Med 2007;57:528–37 doi:10.1002/mrm.21165 pmid:17326183

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Warntjes JB,
    3. Leinhard OD,
    4. West J, et al

    . Rapid magnetic resonance quantification on the brain: optimization for clinical usage. Magn Reson Med 2008;60:320–29 doi:10.1002/mrm.21635 pmid:18666127

    CrossRefPubMed
15. 15.↵
    2. Shinohara RT,
    3. Goldsmith J,
    4. Mateen FJ, et al

    . Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents. AJNR Am J Neuroradiol 2012;33:1586–90 doi:10.3174/ajnr.A2997 pmid:22442041

    Abstract/FREE Full Text
16. 16.↵
    2. Treabă CA,
    3. Bălaşa R,
    4. Podeanu DM, et al

    . Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? Diagn Interv Radiol 2014;20:178–84 doi:10.5152/dir.2013.13313 pmid:24378990

    CrossRefPubMed
17. 17.↵
    2. Eisele P,
    3. Szabo K,
    4. Griebe M, et al

    . Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study. AJNR Am J Neuroradiol 2012;33:1369–73 doi:10.3174/ajnr.A2975 pmid:22576893

    Abstract/FREE Full Text
18. 18.↵
    2. Deoni SC,
    3. Peters TM,
    4. Rutt BK

    . High-resolution T1 and T2 mapping of the brain in a clinically acceptable time with DESPOT1 and DESPOT2. Magn Reson Med 2005;53:237–41 doi:10.1002/mrm.20314 pmid:15690526

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Papanikolaou N,
    3. Papadaki E,
    4. Karampekios S, et al

    . T2 relaxation time analysis in patients with multiple sclerosis: correlation with magnetization transfer ratio. Eur Radiol 2004;14:115–22 doi:10.1007/s00330-003-1946-0 pmid:14600774

    CrossRefPubMedWeb of Science
20. 20.↵
    2. MacKay AL,
    3. Vavasour IM,
    4. Rauscher A, et al

    . MR relaxation in multiple sclerosis. Neuroimaging Clin N Am 2009;19:1–26 doi:10.1016/j.nic.2008.09.007 pmid:19064196

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Larsson HB,
    3. Frederiksen J,
    4. Petersen J, et al

    . Assessment of demyelination, edema, and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. Magn Reson Med 1989;11:337–48 doi:10.1002/mrm.1910110308 pmid:2779421

    CrossRefPubMed
22. 22.↵
    2. Ormerod IE,
    3. Bronstein A,
    4. Rudge P, et al

    . Magnetic resonance imaging in clinically isolated lesions of the brain stem. J Neurol Neurosurg Psychiatry 1986;49:737–43 doi:10.1136/jnnp.49.7.737 pmid:3746304

    Abstract/FREE Full Text
23. 23.↵
    2. West J,
    3. Aalto A,
    4. Tisell A, et al

    . Normal appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. PLoS One 2014;9:e95161 doi:10.1371/journal.pone.0095161 pmid:24747946

    CrossRefPubMed
24. 24.↵
    2. Filippi M,
    3. Rocca MA,
    4. Barkhof F, et al

    ; Attendees of the Correlation between Pathological MRI Findings in MS Workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11:349–60 doi:10.1016/S1474-4422(12)70003-0 pmid:22441196

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Cotton F,
    3. Weiner HL,
    4. Jolesz FA, et al

    . MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46 doi:10.1212/01.WNL.0000046587.83503.1E pmid:12601106

    Abstract/FREE Full Text
26. 26.↵
    2. West J,
    3. Warntjes JB,
    4. Lundberg P

    . Novel whole brain segmentation and volume estimation using quantitative MRI. Eur Radiol 2012;22:998–1007 doi:10.1007/s00330-011-2336-7 pmid:22113264

    CrossRefPubMed
27. 27.↵
    2. West J,
    3. Blystad I,
    4. Engström M, et al

    . Application of quantitative MRI for brain tissue segmentation at 1.5 T and 3.0 T field strengths. PLoS One 2013;8:e74795 doi:10.1371/journal.pone.0074795 pmid:24066153

    CrossRefPubMed
28. 28.↵
    2. Warntjes JB,
    3. Tisell A,
    4. Landtblom AM, et al

    . Effects of gadolinium contrast agent administration on automatic brain tissue classification of patients with multiple sclerosis. AJNR Am J Neuroradiol 2014;35:1330–36 doi:10.3174/ajnr.A3890 pmid:24699093

    Abstract/FREE Full Text
29. 29.↵
    2. Vågberg M,
    3. Lindqvist T,
    4. Ambarki K, et al

    . Automated determination of brain parenchymal fraction in multiple sclerosis. AJNR Am J Neuroradiol 2013;34:498–504 doi:10.3174/ajnr.A3262 pmid:22976234

    Abstract/FREE Full Text